389 completed. 389 Phase 3, 41 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 389 | Completed 389 |
| Phase 2 | 41 | Completed 41 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML | Phase 3 | Completed | The Second Affiliated Hospital of Kunming Medical University | 154 | 2023-11-01 | 2026-09-09 |
| Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities Mesh - spatial repellent impregnated with transfluthrin (2500mg), Information and Education Campaigns (IEC), test and treat malaria cases - Malaria, Childhood ALL | Phase 3 | Completed | The Mentor Initiative | 2400 | 2023-06-05 | 2024-04-23 |
| Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML Azacitidine Combined With Venetoclax and ATRA group - Acute Myeloid Leukemia | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 60 | 2022-10-31 | 2026-06-18 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 199 | 2021-10-13 | 2026-03-18 |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation ABL001 - Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Completed | Novartis Pharmaceuticals | 56 | 2021-05-25 | 2025-10-16 |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Glasdegib, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Completed | Pfizer | 14 | 2021-05-17 | 2023-12-18 |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) Venetoclax, Cytarabine - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | AbbVie | 14 | 2020-10-05 | 2022-05-05 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-11-02 |
| Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes HCL, verapamil 120mg tablet, non-HCL - Type1 Diabetes | Phase 3 | Completed | Jaeb Center for Health Research | 113 | 2020-07-09 | 2024-11-27 |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | Hoffmann-La Roche | 166 | 2020-05-28 | 2026-03-03 |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | AbbVie | 112 | 2020-03-26 | 2026-04-08 |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) IM JZP-458, IV JZP-458 - Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Jazz Pharmaceuticals | 229 | 2019-12-27 | 2023-11-18 |
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Completed | AstraZeneca | 552 | 2019-09-17 | 2026-09-01 |
| A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia (AML), Cancer | Phase 3 | Completed | AbbVie | 60 | 2019-08-15 | 2023-03-20 |
| TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate - Acute Leukemia, Chronic Myelogenous Leukemia (CML) | Phase 3 | Completed | Medical College of Wisconsin | 431 | 2019-06-25 | 2026-11-16 |
| Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT Oral azacitidine, Matched placebo - Acute Myeloid Leukemia, Myelodysplasia | Phase 3 | Completed | University of Birmingham | 326 | 2019-06-14 | 2026-08-14 |
| Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease Ruxolitinib - Steroid Refractory GVHD | Phase 3 | Completed | Yi-Lun Wang | 6 | 2019-01-01 | 2024-03-05 |
| Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig Hizentra - Secondary Immune Deficiency Disorder | Phase 2 / Phase 3 | Completed | Rochester General Hospital | 20 | 2018-11-05 | 2020-08-26 |
| A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Zanubrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | BeiGene | 652 | 2018-11-01 | 2025-03-30 |
| The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML G-SCF - Granulocyte Colony-stimulating Factor, Minimal Residual Disease | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 762 | 2018-09-04 | 2026-11-12 |
Showing 20 of 389. Sign in to see all of them.
Leukemia, Myeloid, Acute (153) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (111) · Leukemia, Lymphocytic, Chronic, B-Cell (97) · Myelodysplastic Syndromes (61) · Lymphoma (56) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (49) · Lymphoma, Non-Hodgkin (42) · Burkitt Lymphoma (35) · Hodgkin Disease (35) · Leukemia, Myeloid, Chronic-Phase (35) · Lymphoma, Follicular (34) · Lymphoma, Large B-Cell, Diffuse (33) · Lymphoma, Mantle-Cell (32) · Multiple Myeloma (32)
Hemic and Lymphatic Diseases (389) · Neoplasms by Histologic Type (388) · Hematologic Diseases (385) · Neoplasms (364) · Leukemia, Myeloid (214) · Immune System Diseases (213) · Lymphatic Diseases (205) · Immunoproliferative Disorders (204) · Lymphoproliferative Disorders (196) · Pathological Conditions, Signs and Symptoms (185) · Leukemia, Lymphoid (184) · Pathologic Processes (181) · Disease Attributes (174) · Chronic Disease (168)
Cytarabine (99) · Cyclophosphamide (76) · Daunorubicin (58) · Methotrexate (57) · Vincristine (44) · Etoposide (42) · Mercaptopurine (39) · Dexamethasone (38) · Doxorubicin (31) · Asparaginase (29) · fludarabine (29) · Prednisone (28) · Rituximab (28) · pegaspargase (26) · Imatinib Mesylate (25)
Children's Oncology Group (26) · Novartis Pharmaceuticals (18) · Hoffmann-La Roche (12) · National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (11) · Fred Hutchinson Cancer Center (9) · German CLL Study Group (9) · St. Jude Children's Research Hospital (9) · European Organisation for Research and Treatment of Cancer - EORTC (8) · AbbVie (7) · Eastern Cooperative Oncology Group (7) · Alliance for Clinical Trials in Oncology (6) · Medical College of Wisconsin (6) · Nanfang Hospital, Southern Medical University (6) · University of Ulm (6)
United States (210) · Germany (120) · France (105) · Canada (99) · Italy (93) · Australia (81) · United Kingdom (80) · Spain (77) · Belgium (64) · Czechia (57) · Poland (57) · Austria (54) · Russia (46) · Israel (44) · Netherlands (41)
Michael Hallek, MD (6) · Qifa Liu (4) · Mary Horowitz, MD (3) · Mary Horowitz, MD, MS (3) · Alan K. Burnett, MD, FRCP (2)
PMID 38620092, PMID 39121442, PMID 37267439, PMID 40266025, PMID 23007406, PMID 24970932, PMID 28751558, PMID 31196847, PMID 31375516, PMID 33131249, PMID 33242441, PMID 35829925, PMID 36184192, PMID 36815378, PMID 37341189, PMID 37890117, PMID 38295280, PMID 38446568, PMID 42085603, PMID 19602710, PMID 20154213, PMID 20625116, PMID 21343560, PMID 21719599, PMID 22649106, PMID 22965967, PMID 23233662, PMID 23620574, PMID 24797299, PMID 24816240, PMID 24916506, PMID 26590194, PMID 26888258, PMID 28273028, PMID 29148893, PMID 29255066, PMID 29284596, PMID 29859851, PMID 29880603, PMID 30337300, PMID 31188727, PMID 31601692, PMID 31612640, PMID 32499241, PMID 32735048, PMID 34596937, PMID 34865212, PMID 35014928, PMID 35235189, PMID 35377947
U10CA098543 (15), 2015 (7), 2016 (7), 2009 (6), 2014 (6), U10CA021115 (6), U10CA095861 (5), 2005 (4), 2008 (4), 2017 (4), 2023 (4), U01HL069294 (4), U10CA032102 (4), U10CA180886 (4), U24CA076518 (4)